24/7 Market News Snapshot 15 September, 2025 – Ocugen, Inc. Common Stock (NASDAQ:OCGN)

September 15, 2025

DENVER, Colo., 15 September, 2025 (www.247marketnews.com) – (NASDAQ:OCGN) are discussed in this article.
Ocugen, Inc. is experiencing a notable rise in its stock price, opening at $1.129 and currently trading at $1.205, reflecting an increase of 12.62% from the previous close of $1.070. With a trading volume exceeding 4.73 million shares, there is evident heightened market interest, suggesting potential momentum for the company. The upward trajectory could be influenced by favorable developments in Ocugen’s pipeline, particularly its focus on advanced therapies for ocular diseases. Traders are encouraged to monitor resistance levels near $1.25, while support is projected around $1.10, indicating promising volatility that could benefit short-term trading strategies.

In a significant development, Ocugen has announced a licensing agreement with Kwangdong Pharmaceutical, granting Kwangdong exclusive commercialization rights for OCU400, an innovative modifier gene therapy targeting retinitis pigmentosa (RP) in Korea. The agreement entails Ocugen receiving upfront fees and development milestones totaling up to $7.5 million, as well as anticipated sales milestone payments exceeding $180 million over the first decade of commercialization. Additionally, Ocugen will earn a 25% royalty on net sales, fostering a strong partnership aimed at maximizing OCU400’s potential.

Dr. Shankar Musunuri, Ocugen’s Chairman and CEO, expressed enthusiasm about the collaboration, highlighting OCU400’s potential for transforming treatment options for patients facing vision loss. Kwangdong, recognized for its extensive range of healthcare products and innovative research efforts, aligns perfectly as a partner for Ocugen. CEO SungWon Choi emphasized the importance of this collaboration in enhancing their ophthalmology portfolio and facilitating access to critical treatments in Korea.

Currently advancing through Phase 3 clinical development, OCU400 is on track for a Biologics License Application filing in the U.S. set for 2026, with Kwangdong planning to utilize Ocugen’s clinical data for swift regulatory submission to the Korean market post-trials. This partnership represents a substantial stride toward addressing unmet medical needs and reinforces Ocugen’s dedication to delivering transformative therapies for patients worldwide.

Related news for (OCGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.